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Abstract 
We studied deletion and monosomy of chromosome 7 in 150 patients with 
myeloproliferative diseases. We found 8/150 patients with monosomy 7 by 
cytogenetics and 4/150 with deletions of the long arm of chromosome 7 by 
restriction fragment length polymorphism (RFLP) analysis performed with 
Southern and polymerase chain reaction. To overcome limitation of RFLP 
analysis, we restricted loss of heterozygosity study with microsatellites to 45 
patients, observing deletion 7q31.1 in 7/45 patients. In all patients with 
molecular alterations the deletion was observed only in myeloid cells, while 
the monosomy was detected in both myeloid precursor and lymphocytes. 
This finding suggests a CD34-totipotent stem cell origin for the monosomy 
and a colony forming unit – granulocyte, erytrocyte, monocyte, 
megakaryocytes (CFU–GEMM) stem cell origin for the deletions. 
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Abbreviations: LOH, loss of heterozygosity; t-AML, therapy related acute 
myeloid leukemia; t-MDS, therapy related myelodysplastic syndromes; PCR, 
polymerase chain reaction; CML, chronic myeloid leukemia; ET, essential 
thrombocytemia; PV, polycytemia vera; RFLP, restriction fragment length 
polymorphism; MF, myelofibrosis; TSG, tumor suppressor gene; CFU–
GEMM, colony forming unit – granulocyte, erytrocyte, monocyte, 
megakaryocytes 
1. Introduction 
Monosomy of chromosome 7 or partial deletion of the long arm of 
chromosome 7 are often observed in patients with myelodysplastic 
syndromes (MDS) and acute myeloid leukemia (AML) after exposure to 
mutagenic agents or radiation therapy [1] and are more frequently present in 
therapy related myelodysplastic syndromes (t-MDS) and therapy related 
acute myeloid leukemia (t-AML) [2]. 
Molecular analysis of the 7q deletions, in myeloid leukemias, has recently 
shown that at least three regions of the long arm of chromosome 7 are 
involved: 7q22, 7q31.1, and 7q36 [3]. 
A recessive mechanism of tumorigenesis has been suggested for these as for 
many other deletions [4] and these chromosomal abnormalities have been 
associated with a rapid progression of the disease, and a poor response to 
therapy [5]. 
The cell origin of MDS and AML could be either the CFU–GEMM stem cell or 
the CD34-totipotent stem cell, but neither of these possibilities has yet been 
proved [6]. 
In our patients, we made a careful determination of the presence or the 
absence of abnormalities in stem cells, committed cells and derivative cells. 
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Indeed myeloid cells were separated from lymphocytes with antibodies 
conjugated to magnetic beads to obtain a pure fraction that we considered as 
tumoral cells while lymphocytes were considered the normal counterpart. 
In this report, we studied 150 patients affected by myeloproliferative diseases 
to search for monosomy and deletions of chromosome 7 by cytogenetics, 
Southern blot and polymerase chain reaction (PCR) of restriction fragment 
length polymorphism (RFLP). 
The finding of a small number of deletions, 4/150 (2.7%) is due to the need of 
large amount of DNA and to a low informativeness of RFLP markers (whose 
heterozygosity is lower than microsatellites). 
These limitations led us to study loss of heterozygosity (LOH) with 
microsatellite markers using a fluorescent PCR system on 45 patients with 
MDS, AML, and t-AML since microsatellites are highly informative [7]. 
Moreover microsatellites will also be useful to narrow the region, where to 
search for a putative tumor suppressor gene (TSG). 
2. Patients materials and methods 
2.1. Patients 
One hundred and fifty patients with myeloproliferative diseases were studied 
for chromosome 7 alterations. 24 patients were secondary AML, 43 MDS, 31 
de novo AML, 29 chronic myeloid leukemia, 7 essential thrombocytemia (ET), 
12 polycytemia vera (PV) and 4 myelofibrosis (MF). 
2.2. Cytogenetics 
Chromosome analysis on all 150 patients was performed on the bone marrow 
of the patients, without any stimulation, and this has been considered as the 
karyotype of the myeloid cells. Cytogenetics analysis of the cultured 
 4 
peripheral blood cells stimulated by 12-O-tetradecanoylphorbol-13-acetate 
(TPA) for few days as described [8], was carried out only to study the 
karyotypes of the lymphocytes. Chromosome were G-banded with Wright 
stain or R-banded with acridine orange. Karyotypes were described according 
to ISCN nomenclature [9]. 
2.3. Cell separation 
Peripheral blood cells from these patients were separated in lymphocytes and 
myeloid cells either by ficoll gradient or by mini macs columns and 
monoclonal antibodies for the myeloid antigens CD15 and CD33 on magnetic 
beads. 
Fractions were smeared and Giemsa colored for microscopical examination 
to detect cell separation, more than 95% myelomonocytic cells were 
requested to include these samples as tumor cells, normal cell were mostly 
lymphocytes. 
2.4. DNA 
DNA was extracted from the two fractions by Hirt buffer, proteinase K, 
phenol–chloroform extraction and ethanol precipitation as described [10]. 
PCR for RFLP studies was performed as described in Ref. [11] with 30 cycles 
at 93°C for 1 min, 55°C for 1 min and 72° for 1 min. 
2.5. Microsatellites analysis 
Microsatellites analysis was made on 45 patients with MDS, AML, t-AML with 
12 microsatellites mapped in 7q22-7q31.1. One primer of each pair was 
labeled with a fluorescent marker (hex, 6-fam or tet) to obtain a fluorescent 
product of amplification. 
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PCR was performed in a 50 µl mixture containing 10 pmol of each primer, 
200 µM dNTPs, 1.5 mM MgCl2, 1.25 U TaqGold polymerase (Perkin Elmer, 
Foster City, CA), 1×PCR buffer (10 mM Tris–HCl pH 8.3, 50 mM KCl) and 20 
ng of DNA template. Thirty-nine cycles of denaturation at 94°C for 1 min, 
annealing 55°C for 1 min, and extension 72°C for 1 min were carried out. 
Three microliters of fluorescent PCR product were run on the fluorescent 
Capillary System ABI Prism 310 (Applied Biosystem, Foster City, CA), results 
were evaluated using the Gene Scan Software. 
LOH was assessed comparing the difference in the height of allele peaks 
between normal and tumor samples according to mathematic model 
described by Canzian et al. [12] and an example is shown in Fig. 1. 
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Fig. 1. Example of microsatellite analysis (D7S501). Different CA repeats of the two 
alleles are shown as two peaks with different molecular weights (horizontal scale). 
LOH is shown by the loss of the second allele in the tumor sample. 
 
3. Results 
We identified by cytogenetics, monosomy of chromosome 7 in 8/150 patients 
(3 t-AML, 2 AML, and 3 MDS); no deletions of chromosome 7 were found. 
Southern blot analysis on all patients was made with met oncogene (7q31.1) 
as probe and we found 3/150 patients with deletion in this locus (2 t-AML and 
1 MDS). Other probes used, were collagen gene COL1A2, multidrug 
resistance gene, erytropoietin gene and elastin gene. No deletions were 
found with these probes, all of them are centromeric to the met locus. 
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PCR with RFLP study identified only 1/150 patients with LOH in 7q22 (t-
AML). 
Microsatellite analysis was carried out on 45 patients and LOH was observed 
in 7/45 patients (Fig. 2). These patients were affected by: 3 t-AML, 2 AML, 
and 2 MDS.  
 
Fig. 2. Summary of allelic 
losses mapped on 7q22–31.1 in myeloproliferative diseases. Only cases with LOH in 
at least one locus are illustrated. 
The most deleted region is in 7q31.1 around D7S2554, found in 5/7 patients. 
All deletions seem to be interstitial since all patients retained the more 
telomeric region 7q35–36 studied with a RFLP of the beta chain T-cell 
receptor gene [13]. 
In only 1/7 patients the deletion was found also in 7q22 (since only 2 
microsatellites are located in this region) as shown in Fig. 3. 
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Fig. 3. Graphic representation of human chromosome 7q22–31.3 and approximate 
position of microsatellite repeats. The histogram shows the percent of LOH over 
informative cases, studied with microsatellite analysis. The most deleted region is 
between D7S2418 and D7S655 with loss of microsatellite D72554 in 5 out of 38 
informative patients (13%). 
 
4. Discussion 
The results obtained suggest some observations on the cellular origin of 
chromosome 7 monosomy and deletions. The absence of deletions in 
peripheral lymphocytes (derived from the totipotent stem cell as the myeloid 
precursor CFU–GEMM) argues against a CD34-totipotent stem cell origin of 
the deletion and suggests a CFU–GEMM cell origin. 
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Cytogenetics studies made on lymphocytes of the patients with monosomy 7 
seem to show, on the other side, that the deletion starts in a CD34-totipotent 
stem cell, since the monosomy is observed both in lymphocytes and CFU–
GEMM derived myeloid cells. 
The studies of LOH in tumors are made to identify putative TSGs. Many 
studies have found a higher rate of LOH than of TGSs. This may be due to 
many problems in the identification of candidate TSGs, because they may be 
inactivated by different mechanisms, including small deletions, point mutation, 
homozygous deletion and hypermethylation of promoter sites [14]. 
The clinical influence in patients with LOH and monosomy of different 
chromosomes is not yet completely clear, as discussed in Refs. [15 and 16]. 
In our study the clinical course of patients with chromosome 7 alterations has 
been, in all patients, very aggressive with a poor response to the therapy and 
a short survival. 
We identified by cytogenetics monosomy of chromosome 7 in 8/150 patients 
(3 t-AML, 2 AML and 3 MDS); 5/8 patients with monosomy were affected by 
AML and t-AML at the time of cytogenetics finding. 
The other three patients developed a very aggressive AML after a latency 
from the diagnosis of MDS, of 3, 8 and 14 months. All three patients had a 
very short survival after the diagnosis of AML. 
Considering also the 11 patients with deletions (7q22, 7q31, and 7q31.1) our 
results showed that 19/150 (12.6%) patients had alterations of chromosome 7 
(monosomy and deletions). 
 10 
The most deleted region was identified around the genetic locus D7S2554, 
this LOH was found in 5/7 patients with deletions detected by microsatellites 
analysis. 
Also these patients had a very poor clinical course but one patient with MDS, 
alive after 8 yr, showed deletions in D7S2418, D7S2554 and in the met locus 
(Southern blot, data not shown). 
Further studies with newly identified markers will help to search for 
differences in the deletion of this patient and will narrow the minimal region of 
loss in MDS, AML, and t-AML. 
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